Next-generation sequencing uncovered 3 subtypes of epidermal growth factor receptor–mutant stage 2 and 3 non–small cell lung cancer (NSCLC) that predicted patient outcomes to adjuvant therapy.
Several biomarkers identified by comprehensive genomic profiling were found to predict efficacy and toxicity of chemo-radiotherapy in patients with non–small cell lung cancer (NSCLC), with progression ...
First-line serplulimab and bevacizumab combined with nab-paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer: A phase II trial. This is an ASCO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results